Thomas Danhorn, PhD

Publications

• Chen N, Tyler LC, Le AT, Welsh EA, Fang B, Elliott A, Davies KD, Danhorn T, Riely GJ, Ladanyi M, Haura EB, Doebele RC. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. Mol Cancer Ther. 2024 Jan 3;23(1):92-105. PubMed PMID: 37748191
• Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW. Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer Res Commun. 2024 Aug 1;4(8):1919-1932. doi: 10.1158/2767-9764.CRC-24-0027. PMID: 38984891; PMCID: PMC11298703.
• Hawkins HJ, Yacob BW, Brown ME, Goldstein BR, Arcaroli JJ, Bagby SM, Hartman SJ, Macbeth M, Goodspeed A, Danhorn T, Lentz RW, Lieu CH, Leal AD, Messersmith WA, Dempsey PJ, Pitts TM. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). PLoS One. 2024 Apr 10;19(4):e0298808. doi: 10.1371/journal.pone.0298808. PMID: 38598488; PMCID: PMC11006186.
• Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer. bioRxiv. 2023 Apr 6. PubMed PMID: 37066339
• Assante A, Lkhagvadorj K, Clambey ET, Danhorn T, Merrick DT, Keith RL, New ML, Degregori J, Miller YE, Ghosh M. Reduced Progenitor Function and Altered Immune Landscape Contribute to Field Cancerization of Lung Adenocarcinoma. Am J Respir Crit Care Med. 2023 Oct 15;208(8):903-905. PubMed PMID: 37639330